Overview: Anti-IA-2 Antibody TestIntroduction: The Anti-IA-2 Antibody Test detects antibodies linked to type 1 diabetes, which may cause excessive thirst, fatigue, or weight loss. Aligned with 2023 ADA guidelines, it uses an immunoassay for high sensitivity, aiding in autoimmune screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in immunology for patients with suspected type 1 diabetes.
Other Names: Anti-IA-2 Assay, Insulinoma-Associated Antigen Antibody Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Autoimmune diabetes testing began in the 1970s with islet cell antibodies. Anti-IA-2 assays emerged in the 1990s, and by the 2000s, immunoassays improved specificity for type 1 diabetes.
Purpose: Diagnoses type 1 diabetes, guides treatment, and monitors autoimmune activity in patients with thirst, fatigue, or weight loss.
Test Parameters: 1. Insulinoma Associated Antigen
Pretest Condition: No fasting required. Collect serum or saliva at any time. Report symptoms like thirst or weight loss, and list medications like insulin or immunosuppressants.
Specimen: 2-5 mL serum (SST) or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document diabetes symptoms, autoimmune disease history, or family history of type 1 diabetes. Include current medications, especially insulin or immunosuppressants.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for insulin therapy or further testing.
Procedural Considerations: Uses an immunoassay to measure anti-IA-2 antibodies. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Immunosuppressants may suppress antibody levels, causing false negatives. Hemolysis or improper storage can degrade samples.
Clinical Significance: Positive results confirm type 1 diabetes, prompting insulin therapy. Negative results may require GAD65 or islet cell antibody testing.
Specialist Consultation: Consult an endocrinologist for result interpretation. A pediatric endocrinologist referral is advised for juvenile cases.
Additional Supporting Tests: GAD65 antibody test, HbA1c, or islet cell antibody test to confirm type 1 diabetes or assess glycemic control.
Test Limitations: False negatives may occur with early disease or immunosuppressive therapy. Results require clinical correlation.
References: ADA Diabetes Guidelines, 2023; Diabetes Care, Atkinson MA, 2022.
